Theratechnologies Inc. re-affirmed revenue guidance for the fiscal year of 2022. For the year, the company is on track to be in the range of $79 million - $82 million, or growth of the commercial portfolio to be in the range of 13% and 17%, as compared to the 2021 fiscal year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 CAD | +4.22% | -1.14% | -19.16% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.16% | 5.6Cr | |
-0.28% | 9.09TCr | |
-0.92% | 3.9TCr | |
-9.57% | 3.35TCr | |
-17.98% | 1.45TCr | |
-6.74% | 1.32TCr | |
-9.76% | 1.17TCr | |
-47.31% | 1.06TCr | |
+6.52% | 923.36Cr | |
+137.06% | 770.73Cr |
- Stock Market
- Equities
- TH Stock
- News Theratechnologies Inc.
- Theratechnologies Inc. Re-Affirms Revenue Guidance for the Fiscal Year of 2022